Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > SPRC SciSparc > Detailed Quotes

SPRC SciSparc

Watchlist
2.130
-0.084-3.79%
Close 06/30 16:00 ET
2.13000.00%
Post Mkt Price 06/30 16:00 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
2.170
Open
2.170
Turnover
46.78K
Low
2.010
Pre Close
2.214
Volume
22.32K
Market Cap
6.80M
P/E(TTM)
Loss
52wk High
8.500
Shares
3.19M
P/E(Static)
Loss
52wk Low
0.000
Float Cap
6.36M
Bid/Ask %
88.23%
Historical High
8.500
Shs Float
2.98M
Volume Ratio
0.27
Historical Low
0.000
Dividend TTM
--
Div Yield TTM
--
P/B
0.83
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.75%
Amplitude
7.23%
Avg Price
2.096
Lot Size
1
Float Cap
6.36M
Bid/Ask %
88.23%
Historical High
8.500
Shs Float
2.98M
Volume Ratio
0.27
Historical Low
0.000
Dividend TTM
--
P/B
0.83
Dividend LFY
--
Turnover Ratio
0.75%
Amplitude
7.23%
Avg Price
2.096
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer’s disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer’s to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer’s disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
CEO: Adler C.P.A., Oz
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top